Last Updated: July 25, 2026

Details for Patent: 8,357,693


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,357,693 protect, and when does it expire?

Patent 8,357,693 protects REZUROCK and is included in one NDA.

This patent has twenty-two patent family members in nineteen countries.

Summary for Patent: 8,357,693
Title:Pharmacokinetically improved compounds
Abstract:The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
Inventor(s):Alessandra Bartolozzi, Stewart Campbell, Hope Foudoulakis, Brian Kirk, Siya Ram, Paul Sweetnam
Assignee: Surface Logix LLC
Application Number:US11/887,218
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,357,693

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kadmon Pharms Llc REZUROCK belumosudil mesylate TABLET;ORAL 214783-001 Jul 16, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER THROUGH INHIBITING RHO-ASSOCIATED, COILED-COIL CONTAINING PROTEIN KINASE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,357,693

PCT Information
PCT FiledMarch 27, 2006PCT Application Number:PCT/US2006/011271
PCT Publication Date:October 05, 2006PCT Publication Number: WO2006/105081

International Family Members for US Patent 8,357,693

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006230159 ⤷  Start Trial
Brazil PI0622285 ⤷  Start Trial
Canada 2602254 ⤷  Start Trial
China 101208094 ⤷  Start Trial
Costa Rica 9465 ⤷  Start Trial
Eurasian Patent Organization 022875 ⤷  Start Trial
Eurasian Patent Organization 200702048 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.